Collagen-IN-1 has potential for use in the study of platelet-related thrombotic disorders; it acts as a selective collagen inhibitor, non-competitively inhibiting agonist-induced platelet aggregation (IC50 = 1.77 μM), and reduces P-selectin expression, glycoprotein IIb/IIIa activation, and the release of ATP and CD63 from platelets.